Acelity Introduces ALLODERM SELECT DUO™ Regenerative Tissue Matrix
Portfolio enhancement expands upon the industry leading ALLODERM™
Tissue Matrix brand to offer surgeons a new matched tissue matrix option
for bilateral breast reconstruction
SAN ANTONIO–(BUSINESS WIRE)–Acelity, a global advanced wound care and regenerative medicine company,
announced today that ALLODERM SELECT DUOTM Regenerative
Tissue Matrix is now available in the United States. ALLODERM™
Regenerative Tissue Matrix is the nation’s leading biological tissue
matrix for soft tissue reinforcement in breast reconstruction
procedures, with more than 1.4 million implants to date. The
new offering is a matched tissue matrix pair intended for patients
undergoing bilateral breast reconstruction that provides uniform tissue
characteristics, including same donor, shape and thickness, allowing for
a more consistent product experience for both plastic surgeons and
patients.
“Reconstruction is an important part of the recovery process for many
women who undergo mastectomy,” said Allen Gabriel, M.D., board-certified
plastic surgeon at PeaceHealth Medical Group Plastic Surgery, Vancouver,
Washington. “The ALLODERM SELECT DUO™ Tissue Matrix is an enhanced
product offering for bilateral breast reconstruction, which are
approximately 60 percent of all breast reconstructions performed. The
matched pair from a single donor helps surgeons achieve their desired
surgical outcomes and advances the art and practice of this critical
component to women’s restoration and well being.”
ALLODERM SELECT DUO™ Regenerative Tissue Matrix delivers the
regenerative qualities that surgeons have come to trust, while offering
uniform tissue characteristics to better improve the bilateral breast
reconstruction experience. Products in the ALLODERM™ Tissue Matrix
portfolio are made from donated human dermis, processed to remove cells
while preserving the essential biological components and structure of
the dermal matrix to support tissue regeneration. Acelity uses
proprietary processing that allows the matrices to support rapid
revascularization, cell repopulation and white cell migration, offering
surgeons a natural solution for soft tissue support where weakness
exists.
This launch marks the third product advancement to the Acelity breast
reconstruction portfolio in 2016. In May, Acelity launched the ALLODERM
SELECT™ Regenerative Tissue Matrix brand that provides a consistent
shape resulting from advanced cutting technology, a range of thicknesses
to meet clinical needs (thin, medium, thick and x-thick), and an
innovative packaging design that ensures consistently smooth and
straight pieces. ALLODERM SELECT DUO™ is available in the updated
thicknesses and improved packaging. In addition to ALLODERM SELECT™ and
ALLODERM SELECT DUO™ Tissue Matrices, Acelity has initiated a limited
launch of the ARTIA™ Reconstructive Tissue Matrix, a new porcine
acellular dermal matrix, in the U.S. and full launch in Europe.
“For more than 20 years, surgeons have relied on ALLODERM™ Tissue Matrix
as a leading product in breast reconstruction, and Acelity is committed
to further advancing this technology so we can provide women facing
mastectomy with enhanced and effective options,” said Joe Woody,
president and chief executive officer of Acelity. “Our new breast
reconstruction offerings are designed to improve the clinician and
patient experience, and build upon the rich history and renowned
ALLODERM™ Tissue Matrix brand that began with the product’s development
at LifeCell. As part of the Acelity portfolio, we will continue to
invest in innovation and expansion so that women who choose
reconstruction, and the surgeons guiding their care, will have many more
options available to them.”
About Acelity
Acelity L.P. Inc. and its subsidiaries are a global advanced wound care
and regenerative medicine company created by uniting the strengths of
three companies, Kinetic Concepts, Inc., LifeCell Corporation and
Systagenix Wound Management, Limited. Available in more than 80
countries, the innovative and complementary ACELITY™ product portfolio
delivers value through solutions that speed healing and lead the
industry in quality, safety and customer experience. Headquartered in
San Antonio, Texas, Acelity employs more than 5,800 people around the
world.
Contacts
Acelity L.P. Inc.
Kathryn Skeen, +1-210-882-2067
Corporate
Communications
kathryn.skeen@acelity.com
or
Caleb
Moore, +1-210-255-6433
Investor Relations
caleb.moore@acelity.com
